SCHEMBL1992931

SCHEMBL1992931

COc1ccc(C2CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
THRB P10828 1/20 0.55
DRD2 P14416 1/20 0.54
KDM1A O60341 2/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
KCNH2 Q12809 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
HAO1 Q9UJM8 1/20 0.47
CTSK P43235 1/20 0.47
HSD11B1 P28845 1/20 0.47
CAMK2A Q9UQM7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1990897 1.00 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL30688051 1.00 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL30688049 1.00 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL2095118 0.98 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL23483176 0.94 ALDH1A1 (0.55) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL11179383 0.94 ALDH1A1 (0.55) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL1515040 0.93 DRD2 (0.56) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL19681496 0.92 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2THRBDRD2
Bicarbonate SCHEMBL9436232 0.91 ALDH1A1 (0.63) ALDH1A1MAPTSMN1; SMN2THRBDRD2
SCHEMBL1515026 0.89 DRD2 (0.59) ALDH1A1MAPTSMN1; SMN2DRD2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP claimed
CN-117185966-B Method for carrying out open-loop sulfonylation on cycloalkanol 安徽金桐精细化学有限公司 2024-09-24 CN disclosed
US-12024665-B2 Polymer-stabilized liquid crystal composition and use thereof BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) 2024-07-02 US disclosed
US-20240196599-A1 SEMICONDUCTOR DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-06-13 US disclosed
CN-118175839-A Semiconductor device with a semiconductor layer having a plurality of semiconductor layers 三星电子株式会社 2024-06-11 CN disclosed
US-20240116965-A1 ORGANOMETALLIC COMPOUNDS UMICORE AG & CO. KG (DE) 2024-04-11 US disclosed
CN-113666826-B Aryl or heteroaryl methoxylation reaction method 五邑大学 2024-03-26 CN disclosed
CN-117229111-A Dehydroaromatization method for aryl cyclic hydrocarbon 五邑大学 2023-12-15 CN disclosed
CN-117185966-A Method for carrying out open-loop sulfonylation on cycloalkanol 安徽金桐精细化学有限公司 2023-12-08 CN disclosed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 EP disclosed
EP-0030920-B1 ACYL PEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AS WELL AS THEIR MANUFACTURE AND USE CIBA-GEIGY AG (CH) 1984-02-15 EP disclosed
EP-0017760-B1 SOMATOSTATIN ANALOG PEPTIDES, THEIR PREPARATION AND USE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION CIBA-GEIGY AG (CH) 1983-05-11 EP disclosed
WO-1983000333-A1 ANTI-HYPERTENSOR, HETEROCYCLICALLY DI-ORTHOSUBSTITUTED PHENOLS TEULON, JEAN-MARIE 1983-02-03 WO disclosed
EP-0070779-A2 Di-ortho-substituted phenols of which one of the substitutions is a heterocycle, process for their preparation, anti-hypertensive medicines containing them and synthesis intermediates CARPIBEM (CENTRE D'ACTIVITE ET DE RECHERCHE PHARMACEUTIQUE INDUSTRIELLE BIOLOGIQUE ET MEDICALE) Société Anonyme dite: (FR) 1983-01-26 EP disclosed
US-4369179-A TREATMENT OF DIABETES AND GASTROINTESTINAL BLEEDING WITH SOMATOSTATIN DERIVATIVES CIBA-GEIGY CORPORATION (US) 1983-01-18 US disclosed
US-4316890-A Peptides and processes for the manufacture thereof CIBA-GEIGY CORPORATION (US) 1982-02-23 US disclosed
EP-0030920-A2 Acyl peptides and pharmaceutical preparations thereof, as well as their manufacture and use CIBA-GEIGY AG (CH) 1981-06-24 EP disclosed
EP-0017760-A1 Somatostatin analog peptides, their preparation and use, pharmaceutical compositions containing them and their preparation CIBA-GEIGY AG (CH) 1980-10-29 EP disclosed
US-4032568-A PRODUCTION OF 2-HYDROXYNAPHTHALENE-3-CARBOXYLIC ACID BASF AKTIENGESELLSCHAFT (DT) 1977-06-28 US disclosed
US-3994871-A Process for the manufacture of peptides containing cystine CIBA-GEIGY CORPORATION (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116965-A1 ORGANOMETALLIC COMPOUNDS DDT, PPOX, PDCD2L ALDH1A1 2120/4885MAPT 2304/4885SMN1; SMN2 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.